Idiopathic Inflammatory Myopathies · Internal Medicine

Internal Medicine · Clinical Specialties

How it begins

Heterogeneous group of systemic autoimmune diseases that predominantly affect skeletal muscle. Comprehensive analysis of the contemporary classification, pathophysiology, autoantibody profile, clinical manifestations, EULAR/ACR 2017 diagnostic criteria and evidence-based therapeutic strategy.

What it covers

1. · Idiopathic Inflammatory Myopathies
2. Definition, Classification and Nomenclature
3. Epidemiology
4. Molecular and Immunological Physiopathology
5. · 3.1 Polymyositis — Targeted CD8+ T Cytotoxicity
6. · 3.2 Dermatomyositis — Complement-Mediated Vasculopathy
7. · 3.3 Inclusion Body Myositis (IBM) — The Enigma of Inflammation and Degeneration
8. · 3.4 Autoimmune Necrotizing Myopathy (IMNM) — Direct Pathogenic Antibodies
9. Autoantibody Profile — Serological Classification System
10. · 4.1 Myositis Specific Antibodies (MSA)
11. · 4.2 Myositis Associated Antibodies (MAA)
12. Clinical Manifestations
13. · 5.1 Muscle Commitment
14. · 5.2 Cutaneous Manifestations — Exclusive to Dermatomyositis
15. · 5.3 Interstitial Lung Disease (ILD) — The Deadliest Complication
16. · 5.4 Cardiac Compromise
17. · 5.5 Joint Commitment and Other Manifestations
18. · 5.6 Antisynthetase Syndrome (SAS) — Complete Clinical Phenotype
19. Diagnosis — EULAR/ACR 2017 Criteria and Comprehensive Evaluation
20. · 6.1 Laboratory Evaluation
21. · 6.2 Imaging and Electromyography
22. · 6.3 Muscle Biopsy — The Diagnostic Standard
23. Therapeutic Strategy
24. · 7.1 Corticosteroids — Universal First Line (except IBM)
25. · 7.2 Steroid Sparing (Background Immunosuppressants)
26. · 7.3 Biological Therapies and Small Molecules
27. · 7.4 IBM Treatment — The Great Challenge
28. Association with Neoplasias — Oncological Screening
29. · 8.1 Antibody Risk
30. Differential Diagnosis
31. Forecasting, Follow-up and Monitoring
32. · 10.1 Prognostic Factors
33. · 10.2 Monitoring Plan